Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eye Allergies Clear all
Completed No phase listed Observational

Sensitivity of the Home Macular Perimeter (HMP)

NCT00604071
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Lakeland, Florida • Palm Beach Gardens, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational

Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study

NCT06128707
View directory record Official record
Conditions
Motion Sickness
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
20 Years to 40 Years
Enrollment
59 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

NCT00985075
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2009 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients

NCT01697969
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Olopatadine hydrochloride ophthalmic solution, 0.2%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

NCT04709575
View directory record Official record
Conditions
Allergic Rhinitis, Conjunctivitis
Interventions
REGN5713, REGN5714, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Olopatadine on Allergic Tear Mediators

NCT00609128
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 1Phase 2 Interventional

An Autism Study Using Nambudripad's Food Allergy Elimination Treatments

NCT00247156
View directory record Official record
Conditions
Autism, Food Allergies
Interventions
Acupressure treatments and NAET treatments
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
3 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2008 · Synced Jul 23, 2026, 5:19 AM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Building a Database of Results From People Without Eye Problems

NCT02627339
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
10 Years to 90 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Jul 23, 2026, 5:19 AM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 23, 2026, 5:19 AM EDT
Not listed Phase 4 Interventional

Ocular Allergy Treatment Practical Impact Trial

NCT01808768
View directory record Official record
Conditions
Allergic Conjunctivitis, Rhinoconjunctivitis
Interventions
Alcaftadine
Drug
Lead sponsor
Starx Research Center, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Edison, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 23, 2026, 5:19 AM EDT
Withdrawn No phase listed Observational

Correlation of Scheimpflug Densitometry Measurements of Corneal Haze With Disability Glare

NCT02244892
View directory record Official record
Conditions
Vision Disability
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 23, 2026, 5:19 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease

NCT01211977
View directory record Official record
Conditions
Muckle Wells Syndrome, Autoinflammatory, Behcet's Disease
Interventions
XOMA 052
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Morcher Artificial Iris Diaphragms

NCT00812708
View directory record Official record
Conditions
Aniridia, Iris; Deformity
Interventions
Morcher iris diaphragm implantation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

NCT03489941
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
EM-100, Zaditor®, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Test-Retest Variability of Quick Contrast Sensitivity Function Testing

NCT02177669
View directory record Official record
Conditions
Healthy
Interventions
quick Contrast Sensitivity Function test
Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
20 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jul 23, 2026, 5:19 AM EDT